GLP-1 receptor agonists, such as semaglutide (sold under the brand name Ozempic or Wegovy) and tirzepatide (brand name Mounjaro or Zepbound), are medications originally developed for diabetes and now approved for chronic weight management at specific doses
Additionally, there are other little-known benefits of GLP-1 and GIP medications: 1
The 2026 EASO pharmacotherapy update explicitly ranks tirzepatide above semaglutide for weight loss, while supporting semaglutide as the better-documented option for liver fibrosis endpoints in MASH [1]
doi: 10.1016/j.clnu.2022.07.041
This study followed Reporting of Observational Studies in Epidemiology (STROBE) guidelines
Understanding Facial Volume Loss Facial volume loss refers to the gradual reduction of the fat pads, connective tissues, and supportive structures that give the face its natural fullness and contour